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The ability to isolate and propagate influenza virus is an essential tool for the yearly surveillance of
circulating virus strains and to ensure accurate clinical diagnosis for appropriate treatment. The suitability of
MDCK-SIAT1 cells, engineered to express increased levels of -2,6-linked sialic acid receptors, as an alter-
native to conventional MDCK cells for isolation of circulating influenza virus was assessed. A greater number
of influenza A (H1N1 and H3N2) and B viruses from stored human clinical specimens collected between 2005
and 2007 were isolated following inoculation in MDCK-SIAT1 cells than in MDCK cells. In addition, a higher
titer of virus was recovered following culture in MDCK-SIAT1 cells. All A(H1N1) viruses recovered from
MDCK-SIAT1 cells were able to agglutinate both turkey and guinea pig red blood cells (RBC), while half of the
A(H3N2) viruses recovered after passage in MDCK-SIAT1 cells lost the ability to agglutinate turkey RBC.
Importantly, the HA-1 domain of the hemagglutinin gene was genetically stable after passaging in MDCK-
SIAT1 cells, a feature not always seen following MDCK cell or embryonated chicken egg passage of human
influenza virus. These data indicate that the MDCK-SIAT1 cell line is superior to conventional MDCK cells
for isolation of human influenza virus from clinical specimens and may be used routinely for the isolation and
propagation of current human influenza viruses for surveillance, diagnostic, and research purposes.
The ability to isolate and propagate influenza virus is essen-
tial for the yearly surveillance of circulating virus strains and
for further studies, such as antigenic and antiviral sensitivity
analyses. Historically, embryonated chicken eggs have been
used to propagate influenza viruses, and they are still used by
most manufacturers to produce influenza vaccine today (2, 3,
4). Infection of immortalized mammalian cell lines in vitro with
influenza virus has provided an alternative to egg inoculation
(10, 13). Following the threat of an avian-derived H5N1 influ-
enza pandemic, vaccine production via cell culture is currently
being expanded, allowing more rapid production of influenza
vaccine (8, 21, 29, 44).
Cell culture has been the preferred method for laboratory-
based influenza virus isolation since the 1960s, as it is relatively
simple, sensitive, and cost-effective. Many cell lines have been
used, including BHK-21 (14), LLC-MK2 (38), SPJL (40), and
Vero cells (11, 12). Madin-Darby canine kidney (MDCK) cells,
however, have proved to be the easiest to handle, the most
sensitive, and the most reliable cell line (10, 13, 27, 38) and
remain the standard cell line for influenza virus propagation.
Both human and avian influenza viruses can be isolated from
MDCK cell culture with high viral titers (27, 42, 43), which may
be attributed to the fact that both -2,6- and -2,3-linked sialic
acid receptors are expressed on the surfaces of MDCK cells,
and these are the primary receptors for human and avian
influenza viruses, respectively (18, 35). However, unlike human
respiratory cells, the level of -2,6-linked sialic acid receptors
on MDCK cells is relatively low, and thus, MDCK cells are not
an ideal in vitro representation of the human respiratory sys-
tem (1, 7, 19, 40). Matrosovich and colleagues established an
MDCK cell line, MDCK-SIAT1, that was stably transfected
with human CMP-N-acetylneuraminate:-galactoside -2,6-
sialyltransferase, an enzyme that catalyzes the -2,6-sialylation
of galactose on glycoproteins or glycolipids. These MDCK-
SIAT1 cells overexpress the -2,6-linked sialic acid receptor
compared to MDCK cells (25). Enhanced -2,6-linked recep-
tor levels should increase the number of interactions between
human influenza virions and the cell surface, and hence, the
avidity of the binding. This was indirectly demonstrated by
MDCK-SIAT1 cells being more sensitive for assaying human
influenza virus susceptibility to neuraminidase inhibitors than
MDCK cells (25). Increased sensitivity to neuraminidase in-
hibitors was also seen in viruses passaged through another
MDCK cell line transfected with the -galactosidase -2,6-
sialyltransferase I gene (ST6Gal I) (16). In addition, in a small
study with eight A(H3N2), seven A(H1N1), and five B viruses
collected from 1999 to 2004, ST6Gal I cells showed increased
isolation rates with A(H3N2) and B viruses, but not A(H1N1)
viruses, as well as enhanced virus growth with all three types/
subtypes if the samples had previously been grown in MDCK
cells (16). However, neither of these studies addressed the
potential for in vitro modifications to the virus during culture
in cells overexpressing surface -2,6-linked sialic acid recep-
tors, a common feature seen in egg adaptation of viruses,
where mutations of the hemagglutinin (HA) gene occur in
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response to the abundance of -2,3-linked sialic acid moieties
(18).
Possibly for this reason, or because of the lack of further
reports on the usefulness of these cell lines for influenza virus
isolation, few laboratories have adopted MDCK-SIAT1 or
ST6Gal I cells for routine virus isolation or growth. In this
study, we further assessed whether MDCK-SIAT1 cells were a
viable alternative to conventional MDCK cells for isolation
and propagation of recent influenza viruses. We found that
MDCK-SIAT1 cells gave higher isolation rates and greater
growth of influenza virus from human clinical specimens than
MDCK cells. In addition, there was little change in the se-
quence of the HA gene on passaging in this modified MDCK
cell line.
MATERIALS AND METHODS
Cells. MDCK cells (CCL-34; ATCC) and MDCK-SIAT1 cells (kindly pro-
vided by Hans-Dieter Klenk, University of Marburg, Marburg, Germany) were
passaged in Dulbecco’s modified Eagle’s medium/HAM’s F12 Coon’s medium
(SAFC Biosciences) supplemented with 10% (vol/vol) fetal calf serum (FCS), 2
mM L-glutamine, 1 nonessential amino acids, 0.075% (vol/vol) sodium bicar-
bonate, 10 mM HEPES, 50 U/ml penicillin, 50 g/ml streptomycin (SAFC
Biosciences), and 20 g/ml amphotericin B (Fungizone; Bristol-Myers Squibb
Company). The passage medium for MDCK-SIAT1 cells was further supple-
mented with 1 mg/ml G418 sulfate (Geneticin; Gibco). Viral infection studies
were performed in the absence of FCS and G418. Cells were maintained at 37°C
prior to infection and at 35°C following infection.
Clinical specimens and viruses. Influenza A(H1N1), A(H3N2), and B viruses
were received from WHO National Influenza Centers, WHO Influenza Collab-
orating Centres, and other regional laboratories and hospitals in Australia, New
Zealand, and the Asia/Pacific region. A full list of recovered viruses is provided
in the supplemental material. Viruses were received as isolates passaged in cell
culture or as original clinical samples (in which influenza A or B virus had been
detected by immunofluorescence or by reverse transcription [RT]-PCR). Origi-
nal clinical samples were collected as throat swabs, nasopharyngeal swabs, and
throat washes. All clinical specimens and virus isolates were stored at 80°C
prior to use, and clinical samples had been thawed at least once previously.
Virus infection and analyses. MDCK and MDCK-SIAT1 cells (5  105 per
well) were seeded into 12-well plates (Cellstar; Greiner Bio-one) and allowed to
grow to confluence overnight at 37°C in 5% CO2. Monolayers were washed twice
with Ca2/Mg2-free phosphate-buffered saline before incubation with 50 l
virus sample (clinical isolates were inoculated neat; cell- or egg-passaged virus
was inoculated at 1/100 dilution) at 35°C and 5% CO2 for 30 min. After inocu-
lation, 3 ml medium (without FCS and G418) supplemented with 4 g/ml trypsin
was added to each well, and the cells were incubated at 35°C and 5% CO2. The
wells were monitored daily for virus growth by cytopathic effects, and after 4
days, the supernatant was collected and the presence of virus was assessed by
hemagglutination using 1% turkey or guinea pig red blood cells (RBC). For
serial passaging, cell supernatants were passaged another five times in the same
cell line used for isolation before RNA extraction and sequencing. Viral titers in
the supernatant were quantified by 50% tissue culture infectious dose (TCID50)
assay (41) with 10-fold dilutions of supernatant inoculated onto confluent mono-
layers in 96-well plates and allowed to grow for 4 days before being stained with
0.036% (wt/vol) neutral red. The virus was titered using MDCK cells for viruses
that had been grown in MDCK cells and MDCK-SIAT1 cells for viruses that had
been grown in MDCK-SIAT1 cells. All TCID50 assays were performed in trip-
licate.
HA gene sequencing. For RT-PCR, viral RNA was extracted from 140 l of
infected cell culture supernatant or clinical sample using the QIAamp Viral RNA
minikit (Qiagen). A 5-l aliquot of RNA was used to amplify the HA-1 domain of
influenza HA using gene-specific primers and SuperScript III One-Step RT-PCR
with Platinum Taq (Invitrogen). Fragments amplified (and nucleotide positions)
were as follows: H3 HA, 34 to 1101; H1 HA, 1 to 1317; and B HA, 20 to 1119 using
primers H3 (forward, 5-GACTATCATTGCTTTGAGCTAC, and reverse, 5-CT
ATCATTCCCTCCCAACCAT), H1 (forward, 5-AGCAAAAGCAGGGGA
WAA, and reverse, 5-ACAGCTGTGAATTGAGTGTT, or reverse, 5-CCTCAT
AGTCGGCGAAATA), and B (forward, 5-CTAATATCCACAAAATGAAGGC,
and reverse, 5-ACCAGCAATAGCTCCGAAGAAA). The RT-PCR consisted of
1 cycle of 50°C for 30 min and 94°C for 2 min and 35 cycles of 94°C for 30 s, 55°C
for 30 s, and 68°C for 1 min, followed by a final elongation step of 68°C for 7 min.
The amplicons were visualized on a 2% (wt/vol) agarose gel. PCR products were
purified for use in sequencing reactions using exonuclease I-shrimp alkaline phos-
phatase (ExoSAP-IT; USB Corporation). DNA sequencing was carried out using
the above-mentioned primers in a 96-well plate format using an ABI Prism Dye
Terminator III cycle-sequencing kit (Applied Biosystems), followed by the removal
of excess dye terminators with a BigDye XTerminator purification kit (Applied
Biosystems). The sequence was determined using an automated capillary DNA
sequencer (ABI Prism 3700 at the Institute of Medical and Veterinary Science,
Adelaide, Australia). Sequences were assembled using Lasergene Seqman package
IV [DNAStar V7.2.1(1)].
Statistics. The data were analyzed using the MINITAB statistical analysis
program at a confidence interval of 95%. Differences were considered statisti-
cally significant when the P value was 0.05. Median virus titers were compared
using the nonparametric two-tailed Mann-Whitney U test; the number of virus
isolates recovered in each cell line was analyzed using the chi-square test.
Nucleotide sequence accession numbers. The sequences of the HA-1 domain
of the HA genes of all original clinical specimens analyzed by multiple passaging
in the cell lines are available on GenBank/EMBL/DDBJ with accession numbers
provided in the supplemental material.
RESULTS
The rate of isolation and titer of influenza virus from human
clinical specimens are increased after growth in MDCK-
SIAT1 cells compared to MDCK cells. To determine whether
MDCK-SIAT1 cells had a higher rate of isolation of recent
influenza viruses, MDCK-SIAT1 and MDCK cells were in-
fected with a total of 125 stored clinical specimens (previously
confirmed to be influenza virus positive) in duplicate collected
during the period from 2003 to 2007 [39 A(H1N1), 53
A(H3N2), and 33 B]. Following 4 days in culture, the super-
natants were analyzed for influenza virus by TCID50 (per-
formed in the same cell line used for isolation). Viruses were
considered to have grown successfully if the log10 TCID50/ml
was 2. Of the stored clinical samples, 74% of A(H1N1), 91%
of A(H3N2), and 39% of B viruses were successfully recovered
in at least one of the cell lines (Fig. 1A). No viruses were
isolated exclusively in MDCK cells. Two-thirds of the viruses
grew in both cell lines, and the remaining viruses were recov-
ered only in MDCK-SIAT1 cells (Fig. 1A). There was no
correlation between the year of isolation and cell line recovery
nor any correlation between virus origin and recovery patterns
for A(H1N1) and B viruses (data not shown). For A(H3N2)
viruses, a yearly breakdown revealed that the isolation pattern
of the viruses appeared to be changing, particularly between
2006 and 2007, with a significant reduction in the ability of
MDCK cells to isolate 2007 viruses compared to 2006 viruses
(P  0.005), unlike MDCK-SIAT1 cells, which were able to
grow A(H3N2) viruses from both years (Fig. 1B). The median
viral titers of clinical specimens were significantly higher in
MDCK-SIAT1-grown influenza A cultures than in MDCK-
grown cultures for A(H1N1) viruses (P 0.001) and A(H3N2)
viruses (P  0.0005). No significant difference in the titer of B
viruses was detected, but this may have been due to the small
number of B viruses recovered (8 in MDCK cells and 13 in
MDCK-SIAT1 cells) (Fig. 1C).
MDCK cell-passaged and egg-passaged influenza viruses
propagate in MDCK-SIAT1 cells. To determine if MDCK-
SIAT1 cells could support the growth of viruses previously
cultured in MDCK cells or embryonated eggs, MDCK-SIAT1
cells (with MDCK cells as a control) were infected in duplicate
with 10 MDCK cell-passaged viruses [3 A(H1N1), 4 A(H3N2),
and 3 B/Malaysia/2506/2004-like] and 6 egg-passaged viruses [2
A(H1N1), 2 A(H3N2), and 2 B/Shanghai/361/2002-like] iso-
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lated from 2003 to 2007. The supernatants were collected after
4 days and analyzed for virus by TCID50 assay; 9/10 cell-pas-
saged viruses were recovered in MDCK-SIAT1 cells and 10/10
in MDCK cells. One previously cell-passaged virus, B/Malay-
sia/174/2006, did not grow in MDCK-SIAT1 culture and grew
in only one of two infected MDCK wells and thus was elimi-
nated from any further analyses. All egg-isolated viruses grew
in both cell lines. The median viral titers of cell- and egg-
passaged viruses were significantly higher in MDCK-SIAT1-
grown cultures than in MDCK-grown cultures for A(H3N2)
viruses (P  0.005), but no significant difference in growth of
A(H1N1) or B viruses was detected (Fig. 1D).
RBC binding changes after passaging in cell lines. RBC
agglutination is the method most commonly used to detect influ-
enza virus particles in cell culture supernatants. To investigate
changes to HA binding following cell culture of clinical speci-
mens, randomly selected MDCK-SIAT1- and MDCK-passaged
A(H1N1) (n 	 9) and A(H3N2) (n 	 25) viruses from 2005 to
2007 that grew in both cells lines were analyzed for the ability to
agglutinate turkey and guinea pig RBC. Turkey (and chicken)
RBC express high levels of -2,3-linked sialic acid receptors and
lower levels of -2,6-linked sialic acid receptors than human and
guinea pig RBC (19, 26). Following passage of A(H1N1) viruses
in MDCK cells, the majority of viruses were able to agglutinate
both turkey and guinea pig RBC (Fig. 2). One virus, A/Singapore/
32/2006, was unable to agglutinate either type of RBC, possibly
because the virus titer was very low (data not shown). Following
passage of A(H1N1) viruses in MDCK-SIAT1 cells, the majority
of samples agglutinated both turkey and guinea pig RBC (Fig. 2).
One virus, A/Singapore/68/2005, was able to agglutinate only
guinea pig RBC.
Agglutination patterns were different for A(H3N2) viruses
after passage in the two cell lines. The majority of A(H3N2)
virus samples passaged in MDCK cells were able to agglutinate
both turkey and guinea pig RBC, while almost one-quarter of
viruses could agglutinate only guinea pig RBC (Fig. 2). Fol-
lowing passage in MDCK-SIAT1 cells, all A(H3N2) viruses
agglutinated guinea pig RBC. Interestingly, agglutination of
turkey RBC by A(H3N2) viruses passaged in MDCK-SIAT1
cells was variable. Almost half of the viruses also agglutinated
turkey RBC, and the remaining viruses had only partial agglu-
tination with turkey RBCs (Fig. 2). This incomplete agglutina-
tion was characterized by difficulty in determining the titer of
the virus. Repassage of “incomplete” samples isolated in
MDCK-SIAT1 cells into MDCK cells restored the viruses’
ability to agglutinate turkey RBC, while repassage of samples
isolated in MDCK cells into MDCK-SIAT1 cells generally led
to loss of the ability to agglutinate turkey RBC (data not
shown). These data indicate that the incomplete agglutination
patterns observed were a result of the cell passaging and not a
property of the individual viruses.
The HA gene remains unchanged following viral passage in
MDCK-SIAT1 cells. To determine if the passaging of influenza
FIG. 1. Isolation and passaging of influenza virus samples in
MDCK and MDCK-SIAT1 cells. Human clinical specimens and cell-
and egg-passaged influenza virus samples were cultured in duplicate in
MDCK or MDCK-SIAT1 cells for 4 days. The supernatants were
collected, and influenza virus titers were measured by TCID50 assay.
(A) Total number of human clinical virus isolates recovered in each
cell line. N.R., samples not recovered; SIAT1, MDCK-SIAT1 cells.
(B) Recovery of A(H3N2) viruses from stored clinical samples by year
of collection. (C) Titers for individual stored clinical samples (average
of duplicates) isolated in either MDCK (black) or MDCK-SIAT1
(white) cells. (D) Titers for viruses previously isolated in eggs (squares)
or MDCK cells (diamonds) and repassaged in MDCK (black) or
MDCK-SIAT1 (white) cells. The medians are indicated by the hori-
zontal bars. *, P  0.001; **, P  0.005; ***, P  0.0005.
FIG. 2. RBC agglutination after cell culture. Human clinical spec-
imens cultured in MDCK or MDCK-SIAT1 cells were assayed by
hemagglutination assay with either guinea pig or turkey RBC. Shown
are the numbers of hemagglutination-positive samples (titer 
 1) for
each RBC type from MDCK- or MDCK-SIAT1-cultured A(H1N1)
(white) or A(H3N2) (black) viruses. I/C, incomplete agglutination
(thus, the titer was not determined).
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virus in MDCK-SIAT1 cells (or conventional MDCK cells)
resulted in virus-cell adaptations, six A(H1N1), five A(H3N2),
and six B influenza viruses that grew in both cell lines were
passaged five times in each cell line. After each passage, the
cytopathic effect was observed and RBC agglutination was
measured to confirm virus growth. A(H3N2) samples cultured
in MDCK cells agglutinated both turkey and guinea pig RBC
after five passages, while A(H3N2) samples cultured in
MDCK-SIAT1 cells were able to agglutinate only guinea pig
RBC after one passage. Comparison of the HA-1 domains of
the HA gene sequences of isolated viruses at passage 1 and
passage 5 to those of viruses from original clinical specimens
showed that the HA gene of A(H1N1) viruses did not mutate
following a single passage in either cell line. However, two base
pair changes were seen in A(H1N1) viruses following five pas-
sages in MDCK cells (Table 1). Replacement of G with A at
606 bp, leading to an amino acid change, D190N (H3 number-
ing system), was detected in four of six A(H1N1) MDCK-
passaged viruses. A mixed population was detected in another
sample, with replacement of C with G at 426 bp, producing an
N129K mutation. No changes were seen in A(H1N1) viruses
cultured multiple times in MDCK-SIAT1 cells compared to
the sequence of the original clinical specimen. A synonymous
change was detected in one A(H3N2) clinical specimen after
passage in MDCK-SIAT1 cells (T replaced with A), and a
single nonsynonymous change was detected in one A(H3N2)
clinical specimen after passage in MDCK cells (G316A), lead-
ing to an alanine-to-tyrosine change at amino acid 106. These
mutations appeared stable in the cell lines and were detected
after both single and multiple passages (Table 1).
Interestingly, for influenza B viruses, eight base pair changes
resulting in three amino acid changes were observed after
initial passage in both MDCK cells and MDCK-SIAT1 cells
(N197T, S216F, and G230D). Two of the nonsynonymous mu-
tations were present as mixed populations in some of the
cultures (S216F and G230D). Further mutations were detected
after five passages in the two cell lines, with one nonsynony-
mous change in two of six MDCK-passaged viruses (T199I)
and a synonymous change in both MDCK- and MDCK-SIAT1-
passaged viruses (A906G). The HA sequence changes were
seen for the same viruses in both cell lines, suggesting they
represent a general adaptation to cell culture rather than a
specific adaptation to culture in MDCK-SIAT1 cells.
DISCUSSION
In this study, the usefulness of MDCK-SIAT1 cells com-
pared to conventional MDCK cells for isolation of influenza
virus from stored human clinical samples was investigated.
While previous small studies demonstrated some improvement
in isolation rates, few laboratories routinely use MDCK-SIAT1
or the similar cell line ST6Gal I (16, 25). The data reported
here confirmed that MDCK-SIAT1 cells could be used to
isolate influenza A (H1N1 and H3N2) and B viruses more
efficiently from stored clinical specimens than the parental
MDCK cells in a large number of samples collected in 2006 to
2007. The viruses isolated had fewer amino acid mutations in
the HA-1 domain of the HA gene following multiple passages
in MDCK-SIAT1 cells than in MDCK cells. In addition,
MDCK-SIAT1 cells were able to support higher levels of virus
growth for A(H1N1) and A(H3N2) viruses than MDCK cells.
Infection of cells with influenza virus is limited by the num-
ber of virions in the clinical specimen and the avidity of the
interaction between virions and receptors, which comprises
both the individual affinity of the HA for sialic acid-linked
receptors and the number of receptors available on the cell (or
virion) surface. The increased level of -2,6-linked sialic acid
receptors on MDCK-SIAT1 cells should increase the avidity of
the interaction and hence is likely to contribute to a higher
recovery rate for human influenza viruses from stored clinical
samples with MDCK-SIAT1 cells than with MDCK cells. No
pattern was present between influenza A(H1N1) virus recovery
and the year or location of a clinical specimen. However a
yearly breakdown revealed that the receptor specificity of
A(H3N2) viruses appeared to be drifting, with more viruses
recovered in both cell lines in 2006 than in 2007, when the
majority of A(H3N2) viruses were recovered only in MDCK-
SIAT1 cells. There was no significant difference in the log10
TCID50 titers of A(H3N2) samples from 2006 to 2007 recov-
ered in MDCK-SIAT1 cells, suggesting that the amount of
virus in the samples was not a limiting factor (data not shown).
The density of HA on the virion surface may have altered
between 2006 and 2007 A(H3N2) viruses, a feature seen with
some H5N1 viruses (17). Most likely, however, the affinity of
the HA for -2,6-linked sialic acid receptors altered over time.
Reduction in the affinity of A(H3N2) viruses has been reported
previously, with a loss of binding to chicken RBC by A(H3N2)
viruses seen over the past 10 to 15 years (15, 22, 26, 28). This
may be attributed to a reduced affinity for sialic acid-linked
TABLE 1. Sequence mutations in HA gene after passaging in







Cell passage result (no. of viruses with
mutations/total no. of viruses
sequenced)
MDCK MDCK-SIAT1





G316A A106T 1/5 1/5
T75A 1/5 1/5
B
A590C N197T 2/6 2/6 1/6 2/6
C596T T199I 2/6
C647T S216F 3/6b 3/6b 3/6b 1/6b
G689A G230D 2/6b 2/6 1/6 2/6
T45G 1/6 1/6 1/6 1/6
A594G 1/6 2/6 1/6 2/6
A816G 1/6 2/6 1/6 2/6
G843A 1/6 2/6 1/6 2/6
A906G 2/6 1/6 2/6
a Human clinical specimens were passaged five times in either MDCK or
MDCK-SIAT1 cells in duplicate. The HA-1 domain of the HA gene was se-
quenced after passage 1 (P1) and passage 5 (P5), and mutations (silent and those
resulting in an amino acid change) were recorded where there were changes from
the sequence obtained directly from the clinical sample; amino acids are num-
bered in accordance with the H3 numbering system; base pairs are numbered
with reference to actual sequence numbers of each subtype.
b Mixed population.
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receptors, particularly -2,6-linked receptors, which are at
lower levels on chicken (and turkey) RBC than on guinea pig
RBC (26). This antigenic drift appears to be more dramatic in
the viruses assessed in this study, particularly between 2006
and 2007. Changes in HA sequence between A(H3N2) viruses
from 2006 and 2007 viruses have been observed, particularly
K140I, R142G, and N144D, which are in antigenic site 3 and
lie close to the receptor binding region. Although a direct link
between these specific mutations and receptor affinity has yet
to be confirmed, these amino acids are found in a high pro-
portion of A(H3N2) 2007 viruses but rarely in 2006 viruses,
suggesting they may contribute to the observed changes in HA
binding characteristics.
RBC agglutination of viruses isolated from cell or egg pas-
sage is typically used to assess culture-derived modifications
and the specificity of viral HA for influenza virus receptors (18,
15, 22, 26, 28). In addition, HA inhibition assays with RBC are
routinely used to monitor the antigenic drift of influenza vi-
ruses as part of the WHO Global Influenza Program (5).
Therefore, any change in the ability of viruses to bind to RBC
from different species following passage in MDCK and
MDCK-SIAT1 cells is particularly important. Following pas-
sage in MDCK-SIAT1 cells, A(H3N2) viruses showed altered
agglutination patterns, with the majority of A(H3N2) isolates
unable to agglutinate turkey RBC completely. Changes have
often been observed in RBC agglutination patterns following
passage of viruses in embryonated chicken eggs compared to
MDCK cells (18), but this is generally attributed to changes in
HA specificity due to the increased proportion of -2,3-linked
receptors in eggs compared to MDCK cells and produces vi-
ruses equally capable of binding both chicken and turkey RBC
(18). However there were few sequence changes in HA follow-
ing passage in MDCK-SIAT1 cells compared to the original
clinical sample and little variation in HA sequence between
MDCK- and MDCK-SIAT1-passaged A(H3N2) viruses, de-
spite the altered agglutination patterns. This further suggests
that agglutination differences are a feature of passage in
MDCK-SIAT1 cells. Differences in agglutination patterns have
also been reported following passage of A(H3N2) viruses in
Vero cells compared to MDCK cells (36), where viruses grown
in Vero cells lost the ability to agglutinate chicken erythro-
cytes. While viruses isolated from both cell lines had identical
HA-1 (and other gene) sequences, the HA from Vero cell-
derived viruses had a different glycosylation pattern, with oligo-
saccharides of the high-mannose type, unlike MDCK-derived
viruses. When some of these mannose residues were removed
enzymatically, the Vero cell-derived viruses had the ability to
agglutinate chicken erythrocytes restored. No such differences
were observed with A(H1N1) viruses grown in Vero cells (36).
As MDCK-SIAT1 cells were engineered by transfection with
the human CMP-N-acetylneuraminate -galactoside -2,6-
sialyltransferase gene, glycosylation patterns on the HA of
budding viruses may also be altered. Thus, to ensure accurate
detection of A(H3N2) viruses following passage in MDCK-
SIAT1 cells, we advise the use of mammalian RBC for hem-
agglutination assays.
As shown here and previously reported, unlike embryonated
chicken eggs, influenza virus propagation in MDCK cells re-
sults in little genetic variation in the HA-1 gene compared to
the original infecting sample (6, 13, 20, 26, 30, 32, 33, 34, 37,
39). However, two interesting amino acid mutations were de-
tected as a stable change in more than one virus. The D190N
mutation has been previously been reported in egg-passaged
A(H1N1) viruses (9, 31, 33, 24) and had been shown to dom-
inate in egg-passaged A(H1N1) viruses even if it was originally
present as a minor species (33). As the side chain at position
190 of HA interacts with the 9-hydroxyl group of sialic acid
(45), the D190N mutation increases binding to chicken embryo
chorioallantoic membranes and decreases the affinity of virus
for -2,6-linked sialic acid receptors (9). N197 (with T199) is
an N-linked glycosylation sequon in the HA-1 region of recent
influenza B viruses (N-X-T/S; amino acids 196 to 198 for
B/Yamagata lineage and 197 to 199 for B/Victoria lineage).
Although egg-passaged viruses predominantly select for vari-
ants that no longer have this glycosylation site, MDCK cells
can support the growth of virus with or without glycosylation at
position 197 (6, 37). Studies using cell- and egg-passaged vi-
ruses and viruses modified by reverse genetics that contain the
mutation demonstrated that the binding affinity to horse RBC
was inhibited by glycosylation; however, the loss of the glyco-
sylation site did not affect the affinity for -2,3- or -2,6-linked
sialic acid receptors. This suggests a role for steric hindrance at
this amino acid site in the influenza B virus HA that may also
affect the antigenicity of the virus (6, 37). Although we have
sequenced only one sample from each passage in our studies,
the use of high-fidelity Taq and the repeated incidence of the
same mutation after multiple passages in MDCK cells confirm
the importance of the D190N and N197T/T199I mutations.
Analysis of HA sequences from viruses routinely passaged at the
WHO Collaborating Centre in Melbourne in the past 3 years
revealed that D190N occurred in 14% (9/64) of randomly selected
MDCK-passaged viruses while the N197T/T199I mutations have
also been detected in this and other laboratories (23).
This study showed that MDCK-SIAT1 cells, which expressed
enhanced levels of -2,6-linked sialic acid receptors, supported
isolation of more recent human influenza viruses from a large
panel of stored clinical samples and grew viruses to a higher titer
than conventional MDCK cells. Most importantly, virus from
stored clinical specimens that could not be recovered after inoc-
ulation in MDCK cells was recovered after inoculation in
MDCK-SIAT1 cells. Thus, we propose that MDCK-SIAT1 cells
or a similar line, such as ST6Gal-1 cells, be used routinely, along
with or even in place of conventional MDCK cells, to isolate
human influenza viruses to ensure an accurate representation of
currently circulating influenza virus strains. This may be increas-
ingly important if difficulty in isolating A(H3N2) viruses in
MDCK cells, as seen in recent years, continues. Further studies
will, however, be required to determine if MDCK-SIAT1 and
other equivalent cell lines are as efficient as MDCK cells in iso-
lating and propagating avian influenza viruses, such as A(H5N1)
viruses from humans. While these cell lines have been shown to
express slightly lower or similar levels of -2,3-linked receptors
(the receptor for avian influenza viruses) (16, 25), no comprehen-
sive evaluation has been performed to date.
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